Work

Supplementary Figure 1 from A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

Year: 2023

Type: supplementary-materials

Abstract: B: The dashed line represents 5 CTCs/7.5 mL. C: White circles indicate the location of the lymph node lesion with documented PR, demonstrating a 46% reduction in size from baseline. CT, computerized tomography; CTC, circulating tumor cells; PR, partial response; PSA, prostate-specific antigen.

DOI: 10.1158/1078-0432.22480518.v1

Authors: Debashis Sarker, Nancy A. Dawson, Ana M. Aparicio, Tanya B. Dorff, Allan J. Pantuck, Ulka N. Vaishampayan, Lynn Henson, Lakshmi Vasist, Sumita Roy-Ghanta, Michele Gorczyca, Whitney York, Gopinath Ganji, Jerry Tolson, Johann S. de Bono

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361939266

Cites:

Cited by:

Related to: 10